Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-11-15
2011-12-06
Gamett, Daniel C (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S019300, C514S169000, C514S313000
Reexamination Certificate
active
08071547
ABSTRACT:
The invention relates to novel compositions comprising alpha-fetoprotein (AFP) and methods for preventing, treating or inhibiting a malignant neoplasm expressing an alpha-fetoprotein receptor (AFPR) with or without multidrug resistance. Compositions comprising a non-covalent complex of an exogenous AFP, and at least one apoptosis-inducing agent selected from the group comprising mitochondrial membrane permeabilizing agents, mitochondrial pore opening inducing agents, ionophores, caspase 9 activators, caspase 3 activators and retinoids, are provided, wherein the at least one apoptosis-inducing agent reversibly binds to the exogenous AFP. The invention also provides for a process for butanol extraction of porcine alpha-fetoprotein obtained from blood and amniotic fluid extracted during early embryogenesis.
REFERENCES:
patent: 6534479 (2003-03-01), Murgita
patent: 6599507 (2003-07-01), Strelchenok
patent: 6630445 (2003-10-01), Murgita
patent: 6878688 (2005-04-01), Pak et al.
patent: 2002/0051778 (2002-05-01), Pak et al.
patent: 2003/0186945 (2003-10-01), Pezzuto et al.
patent: 2009/0062227 (2009-03-01), Schonthal et al.
patent: 2009/0233849 (2009-09-01), Benevolensky et al.
Copado et al., J Protein Chem. May 1999;18(4):413-424.
NCBI Accession NP—999482, alpha-fetoprotein [Sus scrofa] May 20, 2004.
Tempero, M., ed., et al. “Everyone's Guide to Cancer Therapy.” 4th Ed. Andrews McMeel Publishing. Jan. 20, 2003: 174.
Haouzi, D., et al. “Mitochondrial permeability transition as a novel principle of hepatorenal toxicity in vivo.” Apoptosis. Oct. 2002;7(5):395-405.
Pak, V. “The Use of AFP—Complexes to Induce Apoptosis in Cancer Cells.” Open Cancer J. 2008;2:12-14.
Obatomi, D.K., et al. “Biochemistry and toxicology of the diterpenoid glycoside atractyloside.” Food Chem Toxicol. Apr. 1998,36(4):335-46.
Ahn, Y.S., et al. “Selective extraction of alkaline phosphatase and 5′-nucleotidase from milk fat globule membranes by a single phase n-butanol procedure.” Prep Biochem. Aug. 1993;23(3):409-19. [Abstract].
Nath, R., et al. “Thapsigargin induces apoptosis in SH-SY5Y neuroblastoma cells and cerebrocortical cultures.” Biochem Mol Biol Int. Sep. 1997;43(1):197-205.
D'Ancona, S., et al. “Effects of atractylosides and bongkrekic acid, inhibitors of mitochondrial adenine nucleotide carrier, on growth and structure of tumor cells (F 10) in vitro.” Fitoterapia. 1989;60(6):509-517.
Luft, A.J., et al. “Distribution of alpha-fetoprotein in fetal plasma and in amniotic and allantoic fluids of the pig.” J Reprod Fertil. Mar. 1984;70(2):605-7.
Mizejewski, G.J. “Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy.” Expert Rev Anticancer Ther. Dec. 2002;2(6):709-35.
Thapsigargin. Product Information Sheet. Sigma-Aldrich. Accessed Mar. 29, 2001. <http://http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Product—Information—Sheet/t9033pis.Par.0001.File.tmp/t9033pis.pdf>, (2009).
Darling, R. J., et al. “Glycosylation of erythropoietin affects receptor binding kinetics: role of electrostatic interactions.” Biochemistry. Dec. 10, 2002;41(49):14524-31 [Abstract].
Dollinger, M., et al. Everyone's Guide to Cancer Therapy: How Cancer is Diagnosed, Treated, and Managed Day to Day, Fourth Edition, p. 174, (2002).
Fulda, S., et al. “Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid.” J Biol Chem. Dec. 18, 1998;273(51):33942-8.
Fulda, S., et al. “Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors.” Cancer Res. Nov. 1, 1997;57(21):4956-64.
Lutsenko, S. V., et al. “Antitumor activity of alpha fetoprotein and epidermal growth factor conjugates in vitro and in vivo.” Tumour Biol. Nov.-Dec. 2000;21(6):367-74.
Mizejewski, G. J. “Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants.” Exp Biol Med (Maywood). May 2001;226(5):377-408.
Mizejewski, G. J. “Biological roles of alpha-fetoprotein during pregnancy and perinatal development.” Exp Biol Med (Maywood). Jun. 2004;229(6):439-63.
Nishi, S., et al. “Immunological and chemical correlation between alpha-fetoproteins from human and several mammalian species.” Ann N Y Acad Sci. Aug. 22, 1975;259:109-18 [Abstract].
Semenkova, L., et al. “Alpha-fetoprotein positively regulates cytochrome c-mediated caspase activation and apoptosome complex formation.” Eur J Biochem. Nov. 2003;270(21):4388-99.
Sotnichenko, A. I., et al. “Water-soluble 2,3,7,8-tetrachlorodibenzo—dioxin complex with human α-fetoprotein: properties, toxicity in vivo and antitumor activity in vitro.” FEBS Letters. 1995 450(1): 49-51.
Tsuboi, S., et al. “High level of expression of alpha-fetoprotein receptor in gastric cancers.” Tumour Biol. 2006;27 (6):283-8. Epub Oct. 6, 2006.
Van Oers, N. S. C., et al. “Isolation and characterization of a distinct immunoregulatory isoform of alpha-fetoprotein produced by the normal fetus.” J Exp Med. Sep. 1, 1989;170(3):811-25.
Constab Pharmaceutical, Inc.
Dann Dorfman Herrell & Skillman
Gamett Daniel C
Rigaut Kathleen D.
LandOfFree
Compositions of alpha-fetoprotein and inducers of apoptosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions of alpha-fetoprotein and inducers of apoptosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions of alpha-fetoprotein and inducers of apoptosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4306077